2019
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry
Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta Haematologica 2019, 143: 40-50. PMID: 31315113, DOI: 10.1159/000500666.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaFront-line therapyComplete responseRelapsed diseaseT-cell lymphomaRefractory patientsInitial treatmentPrimary refractoryOverall survivalPeripheral T-cell lymphoma patientsResponse/stable diseaseT-cell lymphoma patientsAggressive T-cell lymphomaSingle-agent regimensDays of enrollmentObjective response ratePrimary refractory diseaseSecond-line settingSecond-line therapyActive single agentProspective outcome dataSingle-agent therapyLonger overall survivalUnmet medical needGood response
2016
Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides
Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clinical Lymphoma Myeloma & Leukemia 2016, 16: 637-643. PMID: 27637428, DOI: 10.1016/j.clml.2016.08.009.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaFolliculotropic mycosis fungoidesPrevious systemic therapyMycosis fungoidesDisease involvementCutaneous tumorsTumor stageSystemic therapyRefractory cutaneous T-cell lymphomaSubtypes of CTCLSafety of romidepsinObjective response ratePhase II studyAggressive disease courseReview of diagnosisT-cell lymphomaHistone deacetylase inhibitorsII studyComposite endpointDisease courseHistology reportsClinical efficacyUncommon subtypeFavorable outcomePatients
2015
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma (PTCL): final results from the T‐ cell consortium trial
Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose J. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma (PTCL): final results from the T‐ cell consortium trial. British Journal Of Haematology 2015, 172: 535-544. PMID: 26627450, PMCID: PMC5642048, DOI: 10.1111/bjh.13855.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaStem cell transplantationT-cell lymphomaFront-line therapyLine therapyCell lymphomaRefractory peripheral T-cell lymphomaConsolidative stem cell transplantationAngioimmunoblastic T-cell lymphomaAnaplastic large cell lymphomaConventional CHOP chemotherapyPhase II studyStage IV diseaseFront-line settingPhase 2 studyProgression-free survivalInternational Prognostic IndexLarge cell lymphomaFebrile neutropeniaPTCL patientsCHOP chemotherapyLiver transaminasesPartial remissionConsortium TrialII studyCutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal Of Clinical Oncology 2015, 33: 3766-3773. PMID: 26438120, PMCID: PMC4979132, DOI: 10.1200/jco.2015.61.7142.Peer-Reviewed Original ResearchConceptsMF/Sézary syndromeAdvanced-stage MF/Sézary syndromeMedian overall survivalSézary syndromeIndependent prognostic markerOverall survivalPrognostic markerWorse survivalMycosis fungoidesAdvanced MF/SSSurvival rateAdvanced-stage mycosis fungoidesIdentical T-cell clonesStage IIB diseaseStage III diseaseStage IV diseaseSingle-center trialAdvanced-stage patientsIndependent prognostic valueSerum lactate dehydrogenasePrognostic index modelSpecific prognostic markersLarge cell transformationT cell clonesIIB diseaseBelinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal Of Clinical Oncology 2015, 33: 2492-2499. PMID: 26101246, PMCID: PMC5087312, DOI: 10.1200/jco.2014.59.2782.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsDisease-Free SurvivalDrug Administration ScheduleDrug Resistance, NeoplasmFemaleHistone Deacetylase InhibitorsHumansHydroxamic AcidsInfusions, IntravenousKaplan-Meier EstimateLymphoma, T-Cell, PeripheralMaleMiddle AgedNeoplasm Recurrence, LocalSulfonamidesTreatment OutcomeConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaInternational Working Group criteriaOverall response rateT-cell lymphomaPrior therapyOverall survivalGroup criteriaResponse rateEnd pointCommon grade 3Prior systemic therapyPrimary end pointSecondary end pointsNovel histone deacetylase inhibitorStem cell transplantationDuration of responseStandard of careDrug Administration approvalHistone deacetylase inhibitorsEvaluable patientsManageable toxicityAdverse eventsDurable responsesPartial response
2012
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. Journal Of Clinical Oncology 2012, 30: 631-636. PMID: 22271479, DOI: 10.1200/jco.2011.37.4223.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibiotics, AntineoplasticDepsipeptidesDiarrheaDisease-Free SurvivalDrug Administration ScheduleFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLymphoma, T-Cell, PeripheralMaleMiddle AgedNeoplasm Recurrence, LocalPneumoniaTreatment OutcomeVascular DiseasesVomitingYoung AdultConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaPrior systemic therapyCR/CRuSystemic therapyT-cell lymphomaPrior therapyComplete response/unconfirmed complete responseResponse ratePrior stem cell transplantationEfficacy of romidepsinSingle-agent romidepsinObjective response ratePhase II studyPrimary end pointPhase II trialUnconfirmed complete responseStem cell transplantationIndependent review committeeDrug Administration approvalSelective histone deacetylase inhibitorsHistone deacetylase inhibitorsManageable toxicityII trialOpen label
2011
Polymorphisms in immune function genes and non-Hodgkin lymphoma survival
Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. Journal Of Cancer Survivorship 2011, 6: 102-114. PMID: 22113576, PMCID: PMC3326600, DOI: 10.1007/s11764-010-0164-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCase-Control StudiesConnecticutCytokinesDisease-Free SurvivalFemaleGene FrequencyGenotypeHumansKaplan-Meier EstimateLymphoma, Non-HodgkinMiddle AgedModels, GeneticPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsSocioeconomic FactorsSurvival AnalysisSurvivorsYoung AdultConceptsNon-Hodgkin lymphomaNHL survivalHazard ratioCytokine genesNon-Hodgkin lymphoma survivalCox proportional hazards modelIncident NHL casesConnecticut Tumor RegistryDisease-free survivalKaplan-Meier curvesRisk of deathProportional hazards modelCombination of polymorphismsImmune function genesIL6 genotypeNHL prognosisTumor RegistryHistologic typeTumor characteristicsDecreased riskSecondary cancersNHL casesTumor interactionCancer occurrenceLymphoma survival
2009
Genetic polymorphisms in the metabolic pathway and non‐Hodgkin lymphoma survival
Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y. Genetic polymorphisms in the metabolic pathway and non‐Hodgkin lymphoma survival. American Journal Of Hematology 2009, 85: 51-56. PMID: 20029944, PMCID: PMC2964927, DOI: 10.1002/ajh.21580.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overArylamine N-AcetyltransferaseConnecticutCytochrome P-450 CYP2E1FemaleFollow-Up StudiesGenotypeGlutathione S-Transferase piGlutathione TransferaseHumansIsoenzymesKaplan-Meier EstimateLeukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularMiddle AgedPolymorphism, Single NucleotideProportional Hazards ModelsRegistriesYoung AdultConceptsNHL survivalHazard ratioLymphoma survivalChronic lymphocytic leukemia/small lymphocytic lymphomaNon-Hodgkin lymphoma survivalCox proportional hazards modelConnecticut Tumor RegistryKaplan-Meier curvesGenetic polymorphismsSmall lymphocytic lymphomaProportional hazards modelGlutathione S-transferaseCytochrome P450NHL prognosisN-acetyltransferasesTumor RegistryTumor characteristicsIncident casesLymphocytic lymphomaMetabolic pathwaysHazards modelSurvival analysisDrug metabolismEnvironmental carcinogensSurvival